Trial Profile

A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2025 According to Xentria media release, this Study has been selected for a thematic poster session at the 2025 American Thoracic Society (ATS) Conference. The study will be presented on Monday, May 19, highlighting key advancements in Xentria's investigational monoclonal antibody therapy for pulmonary sarcoidosis.
18 Mar 2025 According to Xentria media release, the company announced the successful completion of enrollment. The study successfully enrolled 39 patients across 17 centers in 4 countries, surpassing initial enrollment targets.
18 Mar 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com